File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment

TitleChanges of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment
Authors
Issue Date2014
PublisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH
Citation
Journal of Gastroenterology and Hepatology, 2014, v. 29 n. 5, p. 1028-1034 How to Cite?
AbstractBACKGROUND: Hepatitis B surface antigen (HBsAg) kinetics during long-term entecavir therapy has not been well investigated. METHODS: We described the cumulative serologic, virologic and biochemical outcomes and the occurrence of signature entecavir mutations among 222 Chinese treatment-naive chronic hepatitis B (CHB) patient receiving entecavir for up to 5 years. RESULTS: The median rate of HBsAg reduction over 5 years was 0.125 log IU/mL/year. Patients with high baseline HBV DNA levels (>/=8 log copies/mL or >/=7.3 log IU/mL), when compared those with baseline HBV DNA <7.3 log IU/mL, had a significantly greater median rate of HBsAg reduction (0.178 and 0.102 log IU/mL/year respectively, p<0.001). The difference in HBsAg decline was most prominent in the first year (0.324 and 0.062 log IU/mL/year respectively, p<0.001). Greater median rates of HBsAg reduction were also found in hepatitis B e antigen (HBeAg)-positive patients when compared to HBeAg-negative patients (0.144 and 0.098 log IU/mL/year, p=0.015), and in patients with high baseline HBsAg levels (>/=3 log IU/mL), when compared with patients with low baseline HBsAg <3 log IU/mL (0.131 and 0.045 log IU/mL/year respectively, p=0.001). The 5-year cumulative rate of HBV DNA undetectability (<20 IU/mL) was 97.1%. There were two cases of entecavir resistance, resulting in a 5-year cumulative resistance rate of 1.2%. CONCLUSION: In contrast to the profound HBV DNA suppression, long-term entecavir treatment only achieve slow decline in serum HBsAg. Although certain patient subgroups exhibit a more rapid HBsAg reduction, additional therapeutic agents are needed to increase the chance of HBsAg seroclearance in CHB.
Persistent Identifierhttp://hdl.handle.net/10722/193874
ISSN
2015 Impact Factor: 3.322
2015 SCImago Journal Rankings: 1.190
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorSeto, WKWen_US
dc.contributor.authorLam, YFen_US
dc.contributor.authorFung, JYYen_US
dc.contributor.authorWong, DKHen_US
dc.contributor.authorHuang, FYen_US
dc.contributor.authorHung, IFNen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorYuen, RMFen_US
dc.date.accessioned2014-01-28T06:30:43Z-
dc.date.available2014-01-28T06:30:43Z-
dc.date.issued2014en_US
dc.identifier.citationJournal of Gastroenterology and Hepatology, 2014, v. 29 n. 5, p. 1028-1034en_US
dc.identifier.issn0815-9319en_US
dc.identifier.urihttp://hdl.handle.net/10722/193874-
dc.description.abstractBACKGROUND: Hepatitis B surface antigen (HBsAg) kinetics during long-term entecavir therapy has not been well investigated. METHODS: We described the cumulative serologic, virologic and biochemical outcomes and the occurrence of signature entecavir mutations among 222 Chinese treatment-naive chronic hepatitis B (CHB) patient receiving entecavir for up to 5 years. RESULTS: The median rate of HBsAg reduction over 5 years was 0.125 log IU/mL/year. Patients with high baseline HBV DNA levels (>/=8 log copies/mL or >/=7.3 log IU/mL), when compared those with baseline HBV DNA <7.3 log IU/mL, had a significantly greater median rate of HBsAg reduction (0.178 and 0.102 log IU/mL/year respectively, p<0.001). The difference in HBsAg decline was most prominent in the first year (0.324 and 0.062 log IU/mL/year respectively, p<0.001). Greater median rates of HBsAg reduction were also found in hepatitis B e antigen (HBeAg)-positive patients when compared to HBeAg-negative patients (0.144 and 0.098 log IU/mL/year, p=0.015), and in patients with high baseline HBsAg levels (>/=3 log IU/mL), when compared with patients with low baseline HBsAg <3 log IU/mL (0.131 and 0.045 log IU/mL/year respectively, p=0.001). The 5-year cumulative rate of HBV DNA undetectability (<20 IU/mL) was 97.1%. There were two cases of entecavir resistance, resulting in a 5-year cumulative resistance rate of 1.2%. CONCLUSION: In contrast to the profound HBV DNA suppression, long-term entecavir treatment only achieve slow decline in serum HBsAg. Although certain patient subgroups exhibit a more rapid HBsAg reduction, additional therapeutic agents are needed to increase the chance of HBsAg seroclearance in CHB.en_US
dc.languageengen_US
dc.publisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH-
dc.relation.ispartofJournal of Gastroenterology and Hepatologyen_US
dc.rightsThe definitive version is available at www3.interscience.wiley.com-
dc.titleChanges of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatmenten_US
dc.typeArticleen_US
dc.identifier.emailSeto, WKW: wkseto2@hku.hken_US
dc.identifier.emailFung, JYY: jfung@hkucc.hku.hken_US
dc.identifier.emailWong, DKH: danywong@hku.hken_US
dc.identifier.emailHuang, FY: camy@graduate.hku.hken_US
dc.identifier.emailHung, IFN: ivanhung@hkucc.hku.hken_US
dc.identifier.emailLai, CL: hrmelcl@hku.hken_US
dc.identifier.emailYuen, RMF: mfyuen@hku.hken_US
dc.identifier.authoritySeto, WKW=rp01659en_US
dc.identifier.authorityFung, JYY=rp00518en_US
dc.identifier.authorityWong, DKH=rp00492en_US
dc.identifier.authorityHung, IFN=rp00508en_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.identifier.doi10.1111/jgh.12476en_US
dc.identifier.pmid24325451-
dc.identifier.hkuros227480en_US
dc.identifier.volume29-
dc.identifier.issue5-
dc.identifier.spage1028-
dc.identifier.epage1034-
dc.identifier.isiWOS:000334688800023-
dc.publisher.placeAustralia-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats